pEGFP-N1 hMOG-beta2-EGFP
(Plasmid
#160979)
-
PurposeExpresses a human myelin oligodendrocyte glycoprotein isoform beta2 - EGFP fusion protein in mammalian cells
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 160979 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepEGFP-N1
-
Backbone manufacturerTakara Clontech
- Backbone size w/o insert (bp) 4717
- Total vector size (bp) 5356
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameHomo sapiens myelin oligodendrocyte glycoprotein (MOG), transcript variant beta2
-
Alt nameMOG beta-2 isoform (according to Swiss Prot)
-
Alt nameMOG beta-5 isoform (according to UniProt/NCBI)
-
SpeciesH. sapiens (human)
-
Insert Size (bp)639
-
GenBank IDNM_206810
-
Entrez GeneMOG (a.k.a. BTN6, BTNL11, MOGIG2, NRCLP7)
- Promoter CMV
-
Tag
/ Fusion Protein
- EGFP (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site XhoI (not destroyed)
- 3′ cloning site SalI (not destroyed)
- 5′ sequencing primer CMV forward (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pEGFP-N1 hMOG-beta2-EGFP was a gift from Markus Reindl (Addgene plasmid # 160979 ; http://n2t.net/addgene:160979 ; RRID:Addgene_160979) -
For your References section:
Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. Schanda K, Peschl P, Lerch M, Seebacher B, Mindorf S, Ritter N, Probst M, Hegen H, Di Pauli F, Wendel EM, Lechner C, Baumann M, Mariotto S, Ferrari S, Saiz A, Farrell M, Leite MIS, Irani SR, Palace J, Lutterotti A, Kumpfel T, Vukusic S, Marignier R, Waters P, Rostasy K, Berger T, Probst C, Hoftberger R, Reindl M. Neurol Neuroimmunol Neuroinflamm. 2021 Jun 15;8(5). pii: 8/5/e1027. doi: 10.1212/NXI.0000000000001027. Print 2021 Jul. 10.1212/NXI.0000000000001027 PubMed 34131067